Tenayaâs interim MyClimb data suggest 93% of children with MYBPC3-associated HCM have the nonobstructive form with no approved therapies today, highlighting an urgent need for disease-modifying options and better risk stratification. ⨠Whatâs new đ§Ź Genetics that shape outcomes đ Biomarker signal: LVMI đ§ Clinical gap in pediatrics đ§Ş Pipeline context: TNâ201 gene therapy â […]











